• 

  Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement
• 

  How Bad Is Fraud in Alzheimer’s Research? Q&A With Neurologist-Sleuth Matthew Schrag
• 

  Dr. Howard Fillit: The Future of Precision Medicine in Alzheimer’s Disease Treatment
• 

  Alzheimer’s Treatment Plot Twist: When (Healthy) Amyloid Goes Up, Cognitive Decline Slows Down
• 

  Cassava Drug Simufilam Fails First Phase 3 Trial, Halts Second Phase 3 Trial
• 

  A Round-up of Alzheimer’s Drug Trials News From CTAD 2024
• 

  STUDY: Cholinesterase Inhibitors Show Promise for Lewy Body Dementia
• 

  A Common Parasite Could One Day Deliver Drugs to the Brain
• 

  8/11 of the Doctors Who Advised on Kisunla Approval Had Conflicts of Interest
• 

  Athira’s Alzheimer’s Drug Fails in Later-stage Clinical Trial
• 

  For Patients on Discontinued Aduhelm, What Now?
• 

  For Someone With No Alzheimer’s Symptoms, a Weird Doctor’s Visit
• 

  Updates on Alzheimer’s Drug Research from AAIC 2024
• 

  EU Regulators Reject Alzheimer’s Drug Leqembi
• 

  Alzheimer’s Drug Trial Drama: Cassava CEO Resigns After News of Federal Probe

Previous456Next